Q2 2026 saw double-digit revenue and profit growth, with strong cash flow and margins. The Riverpoint Medical acquisition is expected to accelerate growth and profitability, and full-year guidance was raised to reflect robust momentum and expanded medical market exposure.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.